CN107595865A - 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 - Google Patents
一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 Download PDFInfo
- Publication number
- CN107595865A CN107595865A CN201710872510.1A CN201710872510A CN107595865A CN 107595865 A CN107595865 A CN 107595865A CN 201710872510 A CN201710872510 A CN 201710872510A CN 107595865 A CN107595865 A CN 107595865A
- Authority
- CN
- China
- Prior art keywords
- cell
- ginsenoside
- cells
- pharmaceutically acceptable
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title claims abstract description 32
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title claims abstract description 32
- 230000014509 gene expression Effects 0.000 title claims abstract description 26
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 21
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 42
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 41
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 37
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011344 liquid material Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 16
- 239000002904 solvent Substances 0.000 description 8
- 238000010839 reverse transcription Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 102000018348 CC chemokine receptor 5 Human genes 0.000 description 2
- 108010017088 CCR5 Receptors Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000004781 brain capillary Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical class [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | CCR5 mRNA/β-actin mRNA |
溶剂对照组 | 0.81 |
人参皂苷RZ1组 | 2.73 |
人参皂苷RK1组 | 0.84 |
人参皂苷RG5组 | 0.80 |
组别 | 跨内皮细胞穿透率(%) |
溶剂对照组 | 2.7 |
人参皂苷RZ1组 | 23.9 |
人参皂苷RK1组 | 4.4 |
人参皂苷RG5组 | 4.6 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710872510.1A CN107595865B (zh) | 2017-09-25 | 2017-09-25 | 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710872510.1A CN107595865B (zh) | 2017-09-25 | 2017-09-25 | 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107595865A true CN107595865A (zh) | 2018-01-19 |
CN107595865B CN107595865B (zh) | 2018-08-14 |
Family
ID=61058158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710872510.1A Active CN107595865B (zh) | 2017-09-25 | 2017-09-25 | 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107595865B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021098686A1 (zh) * | 2019-11-18 | 2021-05-27 | 深圳先进技术研究院 | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104204194A (zh) * | 2011-12-22 | 2014-12-10 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
WO2016185509A1 (ja) * | 2015-05-15 | 2016-11-24 | 金氏高麗人参株式会社 | ジンセノサイド組成物 |
CN107441106A (zh) * | 2017-09-11 | 2017-12-08 | 青海七彩花生物科技有限公司 | 一种人参皂苷rg5和rz1的药物组合物及在脑保护中的应用 |
CN107502586A (zh) * | 2017-08-15 | 2017-12-22 | 青海七彩花生物科技有限公司 | 一种非编码rna靶标及其抑制剂在制备促进骨髓间充质干细胞成骨分化的药物中的应用 |
-
2017
- 2017-09-25 CN CN201710872510.1A patent/CN107595865B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104204194A (zh) * | 2011-12-22 | 2014-12-10 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
WO2016185509A1 (ja) * | 2015-05-15 | 2016-11-24 | 金氏高麗人参株式会社 | ジンセノサイド組成物 |
CN107502586A (zh) * | 2017-08-15 | 2017-12-22 | 青海七彩花生物科技有限公司 | 一种非编码rna靶标及其抑制剂在制备促进骨髓间充质干细胞成骨分化的药物中的应用 |
CN107441106A (zh) * | 2017-09-11 | 2017-12-08 | 青海七彩花生物科技有限公司 | 一种人参皂苷rg5和rz1的药物组合物及在脑保护中的应用 |
Non-Patent Citations (3)
Title |
---|
SANG MYUNG LEE等: "Anti-inflammatory Effects of Ginsenosides Rg5, Rz1, and Rk1: Inhibition of TNF-α-induced NF-κB, COX-2, and iNOS transcriptional expression", 《PHYTOTHER. RES.》 * |
SANG MYUNG LEE等: "Ginsenosides from Heat Processed Ginseng", 《CHEM.PHARM.BULL.》 * |
乔兵等: "CCR5在慢性乙型肝炎中的研究进展", 《中国免疫学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021098686A1 (zh) * | 2019-11-18 | 2021-05-27 | 深圳先进技术研究院 | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107595865B (zh) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bailly et al. | Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? | |
Slevin et al. | Kupffer cells: inflammation pathways and cell-cell interactions in alcohol-associated liver disease | |
CN104825479B (zh) | 淫羊藿次苷类化合物、其制备方法,及其在促进人细胞产生γ-干扰素作用和在疾病治疗中的应用 | |
Mori et al. | Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection | |
Zeng et al. | Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers | |
US20160310531A1 (en) | Combination of pharmaceutical preparations for tumor chemotherapy | |
CN106265679A (zh) | 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途 | |
CN108498529A (zh) | 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物 | |
CN107595865B (zh) | 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用 | |
KR20150014033A (ko) | 번데기동충하초 추출물을 유효성분으로 함유하는 간 기능 개선 기능성 식품조성물 및 그 제조방법 | |
Li et al. | Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination | |
CN106236796B (zh) | 一种小驳骨有效部位的制备方法及其应用 | |
CN107320554A (zh) | 一种化橘红提取物及其在制备治疗ape1介导的疾病的药物中的应用 | |
CN102755335A (zh) | 一种雷公藤甲素在制备治疗或预防艾滋病毒药物中的应用 | |
CN107595864B (zh) | MIP-1α表达促进剂及在制备促进CIK细胞穿透血脑屏障的药物中的应用 | |
CN102836151A (zh) | Brevilin A作为JAK-STATs信号靶向抑制剂的应用 | |
CN102363044A (zh) | 靶向线粒体的三种蒽醌类物质作为鼻咽癌放射增敏剂的用途 | |
CN103288914B (zh) | 中药饿蚂蝗提取物的制备及抗老年性痴呆药物用途 | |
Hu et al. | Critical reviews on anti-cancer effects of edible and medicinal mushroom phellinus linteus and its molecular mechanisms | |
CN101701218A (zh) | 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用 | |
CN100595200C (zh) | 脱氢卡维丁类化合物及其在医药中的应用 | |
CN1695604A (zh) | 防治神经退行疾病、注意力缺陷多动症和抑郁症的药物 | |
CN105296423B (zh) | 一种cd3ak细胞培养组合物及其培养方法 | |
CN104274828B (zh) | IFN‑α处理细胞所分泌外体在制备抑制肝炎病毒的药物中的应用 | |
CN101259117B (zh) | 一种布拉他辛抗艾滋病病毒的外用贴剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180619 Address after: 211505 D1 building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant after: NANJING QIANNIANJIAN STEM CELL GENE ENGINEERING Co.,Ltd. Address before: 810003 Chengbei Biological Park, Xining, Qinghai, No. 7, No. three road. Applicant before: QINGHAI QICAIHUA BIOTECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180703 Address after: 221006 room 701, block C, 1 software building, Xuzhou Software Park, 6 Quanshan Road, Quanshan, Xuzhou, Jiangsu. Applicant after: XUZHOU PPC PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 211505 D1 building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant before: NANJING QIANNIANJIAN STEM CELL GENE ENGINEERING Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 906, Block C, Building 1, Xuzhou Software Park, 6 Software Park Road, Quanshan District, Xuzhou City, Jiangsu Province, 221000 Patentee after: Xuzhou Lishun Kangda Medical Technology Co.,Ltd. Address before: 221006 room 701, block C, 1 software building, Xuzhou Software Park, 6 Quanshan Road, Quanshan, Xuzhou, Jiangsu. Patentee before: XUZHOU PPC PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A CCR5 expression promoter and its application in the preparation of drugs promoting NK cells to penetrate blood brain barrier Effective date of registration: 20210312 Granted publication date: 20180814 Pledgee: Bank of China Limited by Share Ltd. Xuzhou Copper Mt branch Pledgor: Xuzhou Lishun Kangda Medical Technology Co.,Ltd. Registration number: Y2021320000027 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230303 Granted publication date: 20180814 Pledgee: Bank of China Limited by Share Ltd. Xuzhou Copper Mt branch Pledgor: Xuzhou Lishun Kangda Medical Technology Co.,Ltd. Registration number: Y2021320000027 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |